These positive associations between CXCL9 expression and immune checkpoints were also observed in the mUC cohort2, HCC cohort, HNSCC cohort, and SYSMH‐BC cohort (Figure S10A–I). This evidence concerns the gene CXCL9 and head and neck squamous cell carcinoma.